Lv0
0 积分 2025-10-18 加入
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
1个月前
已完结
In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d
2个月前
已完结
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications
2个月前
已完结
LDL-cholesterol, lipoprotein(a) and high-sensitivity low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events
4个月前
已完结
Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease
4个月前
已完结
Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON‐HF trial
4个月前
已完结
Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
4个月前
已完结
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
5个月前
已完结
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
